Electrophysiological effects of MK-801 on rat nigrostriatal and mesoaccumbal dopaminergic neurons

doi:10.1016/0006-8993(92)91091-R

Brain Research

Volume 590, Issues 1–2, 11 September 1992, Pages 153-163

https://doi.org/10.1016/0006-8993(92)91091-R Get rights and content

Abstract

The electrophysiological effects of the non-competitive $N- methyl - d - aspartate$ (NMDA) antagonist (+)-MK801 (MK-801) on nigrostriatal and mesoaccumbal dopaminergic (DA) neurons were evaluated in chloral hydrate-anesthetized rats. MK-801 (0.05–3.2 mg/kg, i.v.) stimulated the firing rates of 14 (74%) of 19 nigrostriatal DA (NSDA) neurons and all 16 mesoaccumbal DA (MADA) neurons tested. Stimulatory effects of the drug were more prominent on MADA neurons. Interspike interval analysis revealed that MK-801 also regularized DA neuronal firing pattern. Acute brain hemitransection between the midbrain and forebrain attenuated the stimulatory effects of MK-801 on firing rate and blocked the effects on firing pattern. Similar to MK-801, hemitransection itself increased NSDA and MADA cell firing rates and regularized firing pattern. Both i.v. and iontophoretic MK-801 blocked the excitatory effects of iontophoretic NMDA but did not effect excitations caused by the non-NMDA glutamatergic receptor agonists quisqualate and kainate. Iontophoretic MK-801 had no effect alone. These results suggest that the excitatory effects of i.v. MK-801 on DA neuronal activity are not due to direct actions on DA neurons. Glutamatergic projections originating anterior to the hemistransection appear to play a role in the effectrs of MK-801 on DA neuronal activity.

References (56)

M. Carlsson et al.
Interactions between glutamatergic and monoaminergic systems within the basal ganglia — implications for schizophrenia and Parkinson's disease
Trends Neurosci.
(1990)
C.J. Carter
Topographical distribution of possible glutamatergic pathways from the frontal cortex to the striatum and substantia nigra in rats
Neuropharmacology
(1982)
A. Ceci et al.
Phencyclidine-induced activation of ventral tegmental A₁₀ dopamine neurons is differentially affected by lesions of the nucleus accumbens and medial prefrontal cortex
Life Sci.
(1989)
A. Ceci et al.
Activation of the A₁₀ mesolimbic system by the σ-receptor agonist (+)SKF 10,047 can be blocked by rimcazole, a novel putative antipsychotic
Eur. J. Pharmacol.
(1988)
L.A. Chiodo et al.
Evidence for the absence of impulse-regulating somatodendritic and synthesis-modulating nerve terminal autoreceptors on subpopulations of mesocortical dopamine neurons
Neuroscience
(1984)
M.J. Christie et al.
Excitotoxin lesions suggest an aspartatergic projection from rat medial prefrontal cortex to ventral tegmental area
Brain Res.
(1985)
J.M. Deniau et al.
Evidence for branched subthalamic nucleus projections to substantia nigra, entopeduncular nucleus and globus pallidus
Neurosci. Lett.
(1978)
D. Doudet et al.
Activity of nigral dopaminergic neurons after lesion of the neostriatum in rats
Brain Res.
(1984)
A.S. Freeman et al.
The effects of phencyclidine (PCP) and the enantiomers of N-allylnormetazocine (SKF-10,047) on midbrain dopamine neuronal activity
Eur. J. Pharmacol.
(1984)
E.D. French
Effects of phencyclidine on ventral tegmental A₁₀ dopamine neurons in the rat
Neuropharmacology
(1986)

E.D. French et al.

Non-competetive $N- methyl - d - aspartate$ antagonists are potent activators of ventral tegmental A₁₀ dopamine neurons

Neurosci. Lett.

(1990)

E.D. French et al.

Effects of competitive $N- methyl - d - aspartate$ antagonists on midbrain dopamine neurons: an electrophysiological and behavioral comparison to phencyclidine

Neuropharmacology

(1991)

A.A. Grace et al.

Paradoxical GABA excitation of nigral dopaminergic neurons: inderect mediation through reticulata inhibitory neurons

Eur. J. Pharmacol.

(1979)

C. Hammond et al.

Electrophysiological demonstration of an excitatory subthalamonigral pathway in the rat

Brain Res.

(1978)

C. Hammond et al.

Branched output neurons of the rat subthalamic nucleus: electrophysiological study of the synaptic effects on identified cells in the two main target nuclei, the entopenuncular nucleus and the substantia nigra

Neuroscience

(1983)

C.R. Honey et al.

Ketamine and phencyclidine cause a voltage-dependent block of responses to d-aspartic acid

Neurosci. Lett.

(1985)

J.A. Kemp et al.

Noncompetitive antagonists of excitatory amino acid receptors

Trends Neurosci.

(1987)

J. Kornhuber et al.

The cortico-nigral projection: reduced glutamate content in the substantia nigra following frontal cortex ablation in the rat

Brain Res.

(1984)

J. Lipski

Antidromic activation of neurones as an analytical tool in the study of the central nervous system

J. Neurosci. Methods.

(1981)

S. Liljequist et al.

Effect of the NMDA receptor antagonist, MK-801, on locomotor activity and on the metabolism of dopamine in various brain areas of mice

Eur. J. Pharmacol.

(1991)

D.P. O'Brien et al.

Inhibition of non-dopamine cells in the ventral tegmental area by benzodiazepines: relationship to A10 dopamine cell activity

Eur. J. Pharmacol.

(1987)

S.N. Raja et al.

Effects of phencyclidine on the spontaneous activity of monoaminergic neurons

Eur. J. Pharmacol.

(1980)

P. Robledo et al.

Excitatory influence of rat subthalamic nucleus to substantia nigra pars reticulata and the pallidal complex: electrophysiological data

Brain Res.

(1990)

C. Rouillard et al.

Effects of the phencyclidine analogs TCP and BTCP on nigrostriatal dopamine neuronal activity

Eur. J. Pharmacol.

(1990)

E. Scarnati et al.

Pedunculopontine-evoked excitation of substantia nigra neurons in the rat

Brain Res.

(1984)

E. Scarnati et al.

The reciprocal electrophysiological influence between the nucleus tegmenti pedunculopontinus and the substantia nigra in normal and decorticated rats

Brain Res.

(1987)

M.E. Trulson et al.

Phencyclidine suppresses the activity of midbrain dopamine-containing neurons recorded from mouse brain slices in vitro

Eur. J. Pharmacol.

(1987)

F.B. Weihmuller et al.

MK-801 attenuates the dopamine-releasing but not the behavioral effects of methamphetamine: an in vivo microdialysis study

Brain Res.

(1991)

Cited by (129)

CSF dopamine is elevated in first-episode psychosis and associates to symptom severity and cognitive performance
2023, Schizophrenia Research
The hypothesis of dopamine dysfunction in psychosis has evolved since the mid-twentieth century. However, clinical support from biochemical analysis of the transmitter in patients is still missing. The present study assessed dopamine and related metabolites in the cerebrospinal fluid (CSF) of first-episode psychosis (FEP) subjects.
Forty first-episode psychosis subjects and twenty healthy age-matched volunteers were recruited via the Karolinska Schizophrenia Project, a multidisciplinary research consortium that investigates the pathophysiology of schizophrenia. Psychopathology, disease severity, and cognitive performance were rated as well as cerebrospinal fluid concentrations of dopamine and related metabolites were measured using a sensitive high-pressure liquid chromatography assay.
CSF dopamine was reliably detected in 50 % of healthy controls and in 65 % of first-episode psychosis subjects and significantly higher in first-episode psychosis subjects compared to age-matched healthy controls. No difference in CSF dopamine levels was observed between drug-naive subjects and subjects with short exposure to antipsychotics. The dopamine concentrations were positively associated with illness severity and deficits in executive functioning.
Dopamine dysfunction has long been considered a cornerstone of the pathophysiology of schizophrenia, although biochemical support for elevated brain dopamine levels has been lacking. The results of the present study, showing that FEP subjects have increased CSF dopamine levels that correlate to disease symptoms, should fill the knowledge gap in this regard.
Characterisation of methylphenidate-induced excitation in midbrain dopamine neurons, an electrophysiological study in the rat brain
2022, Progress in Neuro-Psychopharmacology and Biological Psychiatry
Methylphenidate (MPH) is a drug routinely used for patients with attention deficit and hyperactivity disorder (ADHD). Concerns arise about psychostimulant use, with dramatic increases in prescriptions. Besides, antipsychotic drugs are often administered in combination with MPH. In this study, we examine the consequences of MPH exposure in combination with dopamine D₂ receptor antagonism (eticlopride) on midbrain dopaminergic neurons in anaesthetised rodents, using in vivo extracellular single-cell electrophysiology. As expected, we show that methylphenidate (2 mg/kg, i.v.) decreases the firing and bursting activities of ventral tegmental area (VTA) dopamine neurons, an effect that is reversed with eticlopride (0.2 mg/kg, i.v.). However, using such a paradigm, we observed higher firing and bursting activities than under baseline conditions. Furthermore, we demonstrate that such an effect is dependent on dual alpha-1 and dopamine D₁ receptors, as well as glutamatergic transmission, through glutamate N-Methyl-D-aspartate (NMDA) receptor activation. Chronic MPH treatment during adolescence greatly dampens MPH-induced excitatory effects measured at adulthood. To conclude, we demonstrated here that a combination of methylphenidate and a dopamine D₂ receptor antagonist produced long-lasting consequences on midbrain dopamine neurons, via glutamatergic-dependent mechanisms.
Ameliorating effects of berberine on MK-801-induced cognitive and motor impairments in a neonatal rat model of schizophrenia
2019, Neuroscience Letters
Citation Excerpt :
This discrepancy can be attributed to the involvement of other neurotransmitters such as GABA and dopamine. Although MK-801 increases dopamine, previous studies show that imbalance at the rotarod test is known as a “non-dopamine dependent” motor function [36,37]. Considering that various receptors and neurotransmitters may be involved in the effects of BBR on motor coordination in the rotarod test, elucidating the exact mechanism underlying this effect will require further studies.
Neonatal administration of MK-801 (NMDA receptor antagonist) results in schizophrenia-like behaviors in rodents. Berberine (BBR) is a herbal alkaloid, which shows many neuroprotective properties in neurodegenerative diseases. The present study was designed to clarify whether systemic administration of BBR improves motor and cognitive disturbances induced by MK-801 treatment. Male Wistar rat pups were treated with intraperitoneal administration of saline (1 ml/kg) as a control group, MK-801 (1 mg/kg), BBR (20 mg/kg) and BBR (20 mg/kg) plus MK- 801 (1 mg/kg). Treatments were administered on postnatal day (P) 6–10 for once daily. To assess motor learning, coordination as well as spatial learning and memory, behavioral evaluation was performed at P55–60, using the rotarod, open field, and Morris water maze paradigm. MK-801 injection led to motor perturbations in both the open field and accelerating rotarod tests, which were restored by BBR. Also, BBR improved learning impairments, although it had no significant effect on the Probe test. Taken together, it can be concluded that BBR produces a neuroprotective effect in rats with MK-801-associated behavioral deficits. Given that the MK-801 exposure demonstrates an animal model of schizophrenia, we suggest that timely BBR administration may act as a potential treatment in schizophrenic patients.
Effects of Low Doses of Ketamine on Pyramidal Neurons in Rat Prefrontal Cortex
2018, Neuroscience
Citation Excerpt :
Ro25 also decreased SO size (F3,27 = 11.16, p < 0.001), but it increased SO frequencies (F3,12 = 8.03, p < 0.01, n = 9, Fig. 4B). Like PCP and MK801, ketamine has been shown to excite midbrain DA neurons (French, 1992; Zhang et al., 1992) and increases PFC DA release (Lindefors et al., 1997; Lorrain et al., 2003; Moghaddam et al., 1997), raising the possibility that part of ketamine’s effect on the PFC is indirectly mediated through DA. Consistent with this possibility, some of PCP’s effects on PFC neurons are blocked by DA receptor antagonists including fluphenazine (Gratton et al., 1987; Kargieman et al., 2007).
Indirect evidence suggests that low doses of ketamine disinhibit (excite) pyramidal neurons in the prefrontal cortex (PFC). In this study, we directly examined the effect of ketamine on PFC pyramidal neurons using simultaneous single-cell and local-field-potential (LFP) recording in chloral hydrate-anesthetized rats. In all animals studied, PFC LFPs showed oscillations (0.3–1.5 Hz) between the active UP state and the relatively quiescent DOWN state, and pyramidal neurons fired preferentially during the UP state. Ketamine (1.25–20 mg/kg, i.v.) inhibited 80% of cells tested and consistently shifted PFC LFPs toward the DOWN state. The inhibitory effect of ketamine was mimicked by MK801, but not by the NR2B-selective NMDA receptor antagonist Ro25-6981. It was not blocked by the dopamine receptor antagonist fluphenazine, the GABA_A receptor antagonist picrotoxinin, or the GABA_B receptor antagonist CGP46381. These results are consistent with the high density of NMDA receptors expressed on PFC pyramidal neurons and our previous studies showing that blockade of NMDA receptors by ketamine inhibits dendritic NMDA receptor-mediated bursting in PFC pyramidal neurons. Thus, in addition to the previously proposed disinhibitory effect mediated through PFC interneurons, our data suggest that ketamine has an inhibitory effect on PFC pyramidal neurons. Our evidence further suggests that the effect is mediated through non-NR2B-containing NMDA receptors, independent of ketamine’s effect on dopamine and GABA transmission. Further understanding of the two opposing effects of ketamine on PFC pyramidal neurons may provide important new insights into its mechanism of action.
Inhibition of kynurenine aminotransferase II reduces activity of midbrain dopamine neurons
2016, Neuropharmacology
Citation Excerpt :
Although only one dose of MLA was administered (4 mg/kg) our results support the notion that blockade of the glycine site of the NMDA receptor, rather than antagonism of the α7* nicotinic receptor, is the mechanism by which KYNA modulates firing rate on midbrain DA neurons. Furthermore, these results are in line with previous studies where systemic administration of NMDA receptor antagonists, such as PCP, MK-801, and L-701,324, are associated with increased firing rate and percent burst firing in midbrain DA neurons (French et al., 1991, 1993; Zhang et al., 1992; Schwieler et al., 2006). In the present study, administration of PF-04859989 was associated with a marked lowering (75%) in whole brain KYNA (5 mg/kg, i.p. n = 5) 5 h after administration.
Kynurenic acid (KYNA), a neuroactive metabolite of tryptophan, is elevated in the brain of patients with psychotic disorders. Therefore, lowering brain KYNA levels might be a novel approach in the treatment of psychotic disorders. The present in vivo electrophysiological study aimed to investigate the effect of an inhibitor of kynurenine aminotransferase (KAT) II, the primary enzyme for KYNA synthesis, on dopamine (DA) neurons in the ventral tegmental area (VTA). Acute administration of the KAT II inhibitor PF-04859989 (5 or 10 mg/kg) was associated with a short-onset, time-dependent decrease in firing rate and burst activity of DA neurons, both parameters reaching a 50% reduction within 45 min. Furthermore, PF-04859989 reduced the number of spontaneously active DA cells as measured 4–6 after administration. Pretreatment with d-cycloserine (30 mg/kg) or CGP-52432 (10 mg/kg) prevented the inhibitory action of PF-04859989 (5 mg/kg) on firing rate and burst firing activity. In contrast, pretreatment with methyllycaconitine (MLA, 4 mg/kg) did not change the response, whereas picrotoxin (4.5 mg/kg) partially prevented the inhibitory effects of PF-04859989 (5 mg/kg, i.v.). Our results show that a specific inhibition of KAT II is associated with a marked reduction in VTA DA firing activity. This effect appears to be specifically executed by NMDA-receptors and mediated indirectly via a GABA(B)-receptor-induced disinhibition of DA neurons. Our findings are in line with the view that endogenous KYNA, by modulation of the NMDA-receptor, exerts important physiological roles in the brain.
Disruption of Dopamine Neuron Activity Pattern Regulation through Selective Expression of a Human KCNN3 Mutation
2013, Neuron
The calcium-activated small conductance potassium channel SK3 plays an essential role in the regulation of dopamine neuron activity patterns. Here we demonstrate that expression of a human disease-related SK3 mutation (hSK3Δ) in dopamine neurons of mice disrupts the balance between tonic and phasic dopamine neuron activity. Expression of hSK3Δ suppressed endogenous SK currents, reducing coupling between SK channels and NMDA receptors (NMDARs) and increasing permissiveness for burst firing. Consistent with enhanced excitability of dopamine neurons, hSK3Δ increased evoked calcium signals in dopamine neurons in vivo and potentiated evoked dopamine release. Specific expression of hSK3Δ led to deficits in attention and sensory gating and heightened sensitivity to a psychomimetic drug. Sensory-motor alterations and psychomimetic sensitivity were recapitulated in a mouse model of transient, reversible dopamine neuron activation. These results demonstrate the cell-autonomous effects of a human ion channel mutation on dopamine neuron physiology and the impact of activity pattern disruption on behavior.

View all citing articles on Scopus

^☆: A preliminary report of portions of this work was presented at the Dopamine 90 satellite meeting of the 11th congress of IUPHAR, Como, Italy, 8–11 July, 1990.

View full text

Research reportElectrophysiological effects of MK-801 on rat nigrostriatal and mesoaccumbal dopaminergic neurons☆

Abstract

Trends Neurosci.

Neuropharmacology

Life Sci.

Eur. J. Pharmacol.

Neuroscience

Brain Res.

Neurosci. Lett.

Brain Res.

Eur. J. Pharmacol.

Neuropharmacology

Neurosci. Lett.

Neuropharmacology

Eur. J. Pharmacol.

Brain Res.

Neuroscience

Neurosci. Lett.

Trends Neurosci.

Brain Res.

J. Neurosci. Methods.

Eur. J. Pharmacol.

Eur. J. Pharmacol.

Eur. J. Pharmacol.

Brain Res.

Eur. J. Pharmacol.

Brain Res.

Brain Res.

Eur. J. Pharmacol.

Brain Res.

Research report
Electrophysiological effects of MK-801 on rat nigrostriatal and mesoaccumbal dopaminergic neurons☆